Hoffmann et al. investigated multidrug resistance gene 1 (MDR1) and ERCC1 gene expression in 108 patients with locally advanced bladder cancer that received cisplatin-based adjuvant chemotherapy [29]. This evidence concerns the gene ERCC1 and urinary bladder carcinoma.